KWKathleen Anne Welsh-Bohmer

Kathleen Anne Welsh-Bohmer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen Anne Welsh-Bohmer has a total of 353 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    International consensus for the assessment of social cognition in neurocognitive disorders: framework definition and clinical recommendations of the SIGNATURE initiative

    by Alessandra Dodich, Andrea Panzavolta, Giulia Funghi, Claudia Meli, Cristina Festari, Thanos Chatzikostopoulos, Christian Chicherio, Florencia Clarens, Fabricio Ferreira de Oliveira, Marco Filardi, et al.

    Socio-cognitive assessment in neurocognitive disorders (NCDs) is rare in clinical practice and no consensus exists as to a uniform operationalization of so


  • Open Access

    The NC Registry for Brain Health: Increasing Access to Brain Health Information and Research in Underserved & Under‐represented Communities

    by Marianne Chanti‐Ketterl, Rachel A Dewees, Andrea Bozoki, Stephen Russ Price, Patrick McPhail Martin, Henry Edmonds, Latorius S Adams, Kelvin Williams, Julie Gaven, Bobbi Matchar, et al.

    Background: Diverse racial/ethnic representation in scientific studies is crucial for generalizability of results and development of potentially effective treatments. Racially diverse registries with research ready individuals have the potential to fill this gap. However, despite having signed up as part of a research registry and being invited to participate in clinical trials, many do not participate. To better understand research participation, the NC Registry for Brain Health surveyed its members to identify the characteristics of those likely to participate in research studies, their views on research, expectations when joining the group, and impediments to participation.Method: The NC Registry for Brain Health has been state‐funded since 2018 with goals of increasing access for all to information and research opportunities in brain health. Focused recruitment to under‐served and under‐represented groups across the State occurs through community outreach events sponsored by a five member university network. An email survey was sent to the 5,946 Registry members enrolled as of October 15, 2021.Result: Approximately 10% (n = 576) responded to this anonymized survey. Most were older women with high levels of formal education (Table 1). Despite the Registry’s demographics of 28% African American enrollees, only 8% of the survey respondents self‐identified as African Americans. Most individuals joined the Registry for the joint purpose of getting involved in research and receiving information about brain health (75%). When asked to describe what “brain health research” means, most reported studies involving dementia risk factors and memory testing. All participants had been approached to get involved in studies, but only 60% recalled getting an email invitation. The biggest impediment noted for participating in studies was inconvenient appointment times. The participants also wanted more available studies and more information about the opportunities.Conclusion: This study suggests that most participants in the Registry are seeking to be informed about brain health and have access to research opportunities at times convenient with their schedules. There was an observed gap between African Americans enrolled in the research registry and those who participated in the survey. Addressing gaps in research involvement of under‐represented groups in research is necessary to achieve inclusive representative science.

  • Raising Awareness of Alzheimer’s Disease and Dementia in Native Americans in North Carolina

    by Kathleen A. Welsh-Bohmer, Goldie Smith Byrd, Rachel Dewees, Andrea C. Bozoki, Patrick M. Martin, Brenda Plassman, S. Russ Price


  • The North Carolina Registry for Brain Health: An actionable strategy to include under‐represented groups in Alzheimer’s disease research

    by Kathleen A Welsh‐Bohmer, Brenda L Plassman, Daniel Kaufer, Grace Byfield, Stephen Russ Price, Michelle G Ries, Adam J Zolotor, Michelle McCart, Amy Pulliam, Johanna Silbersack, et al.

    Background: The North Carolina Institute of Medicine (NC IOM), in response to a legislative mandate, convened a Task Force on Alzheimer’s Disease and Related Dementias (2015/2016) to develop an actionable strategic plan to address the state’s rising rate of Alzheimer’s disease and related dementias and to promote brain health. A recurring state appropriation supports the North Carolina (NC) Registry for Brain Health (Registry), an outcome of the task force plan.Methods: The NC Registry for Brain Health aims to increase public awareness of dementia services, brain health research, and opportunities to participate in clinical investigations. A focus is on under‐served communities traditionally not included in research. The Registry includes investigators from collaborating institutions across the state, including Duke University, East Carolina University, North Carolina A&T State University, the University of North Carolina at Chapel Hill, and Wake Forest School of Medicine. Governance is provided by investigators from each of the collaborating institutions with input from NC IOM, NC DHHS and stakeholders throughout the state.Results: Phase I of the project focused on establishing the Registry infrastructure, including governance, site identification and contracting, programming of the Registry database, and website development. Two public kick off events announcing the Registry were held in June 2019. Phase II has focused on Registry enrollment to under‐served groups through an outreach strategy designed to overcome barriers of communication and trust. To date there have been over 60 outreach events across the state. Current enrollment stands at 4228 enrollees, of whom 34% are self‐identified as minority group members (30.5% African American) and 2.8% identified as Hispanic. As the Registry begins assisting research studies with recruitment, we plan to develop methods to effectively reach individuals with and without easy digital accessConclusions: The NC Registry for Brain Health is growing rapidly and has a diverse membership representative of the state population, demonstrating that groups often under‐represented in research studies have an interest in participating in research. Interfacing with under‐served communities, through outreach events and other face to face interactions, is crucial to ensure the community has access to trusted information when making decisions about potential research participation.

  • Nomenclature for Perioperative Cognitive Disorders: Comment

    by Joseph P. Mathew, Kathleen A. Welsh-Bohmer, Mark F. Newman


  • Open Access

    The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial

    by Daniel K. Burns, Carl Chiang, Kathleen A. Welsh‐Bohmer, Stephen K. Brannan, Meredith Culp, Janet O'NEil, Grant Runyan, Patrick Harrigan, Brenda L. Plassman, Michael Lutz, et al.

    Introduction: Alzheimer's disease (AD) is a continuum with neuropathologies manifesting years before clinical symptoms; thus, AD research is attempting to identify more disease‐modifying approaches to test treatments administered before full disease expression. Designing such trials in cognitively normal elderly individuals poses unique challenges. Methods: The TOMMORROW study was a phase 3 double‐blind, parallel‐group study designed to support qualification of a novel genetic biomarker risk assignment algorithm (BRAA) and to assess efficacy and safety of low‐dose pioglitazone to delay onset of mild cognitive impairment due to AD. Eligible participants were stratified based on the BRAA (using TOMM40 rs 10524523 genotype, Apolipoprotein E genotype, and age), with high‐risk individuals receiving low‐dose pioglitazone or placebo and low‐risk individuals receiving placebo. The primary endpoint was time to the event of mild cognitive impairment due to AD. The primary objectives were to compare the primary endpoint between high‐ and low‐risk placebo groups (for BRAA qualification) and between high‐risk pioglitazone and high‐risk placebo groups (for pioglitazone efficacy). Approximately 300 individuals were also asked to participate in a volumetric magnetic resonance imaging substudy at selected sites. Results: The focus of this paper is on the design of the study; study results will be presented in a separate paper. Discussion: The design of the TOMMORROW study addressed many key challenges to conducting a dual‐objective phase 3 pivotal AD clinical trial in presymptomatic individuals. Experiences from planning and executing the TOMMORROW study may benefit future AD prevention/delay‐of‐onset trials.


  • Open Access

    TOMMORROW neuropsychological battery: German language validation and normative study

    by Heather R Romero, Andreas U Monsch, Kathleen M Hayden, Brenda L Plassman, Alexandra S Atkins, Richard S E Keefe, Shyama Brewster, Carl Chiang, Janet O'Neil, Grant Runyan, et al.

    Introduction: Assessment of preclinical Alzheimer's disease (AD) requires reliable and validated methods to detect subtle cognitive changes. The battery of standardized cognitive assessments that is used for diagnostic criteria for mild cognitive impairment due to AD in the TOMMORROW study have only been fully validated in English‐speaking countries. We conducted a validation and normative study of the German language version of the TOMMORROW neuropsychological test battery, which tests episodic memory, language, visuospatial ability, executive function, and attention. Methods: German‐speaking cognitively healthy controls (NCs) and subjects with AD were recruited from a memory clinic at a Swiss medical center. Construct validity, test–retest, and alternate form reliability were assessed in NCs. Criterion and discriminant validities of the cognitive measures were tested using logistic regression and discriminant analysis. Cross‐cultural equivalency of performance of the German language tests was compared with English language tests. Results: A total of 198 NCs and 25 subjects with AD (aged 65–88 years) were analyzed. All German language tests discriminated NCs from persons with AD. Episodic memory tests had the highest potential to discriminate with almost twice the predictive power of any other domain. Test‐retest reliability of the test battery was adequate, and alternate form reliability for episodic memory tests was supported. For most tests, age was a significant predictor of group effect sizes; therefore, normative data were stratified by age. Validity and reliability results were similar to those in the published US cognitive testing literature. Discussion: This study establishes the reliability and validity of the German language TOMMORROW test battery, which performed similarly to the English language tests. Some variations in test performance underscore the importance of regional normative values. The German language battery and normative data will improve the precision of measuring cognition and diagnosing incident mild cognitive impairment due to AD in clinical settings in German‐speaking countries.


  • Cognitive Enhancement at the Mild Cognitive Impairment Stage of Alzheimer’s Disease

    by Zara Melikyan, Heather Romero, Kathleen A. Welsh-Bohmer

    Alzheimer’s disease (AD) is the most common cause of dementia in aging. Currently, therapeutic interventions are being initiated earlier in the disease course. The rationale of this strategy is to take advantage of the still healthy neuronal systems to optimize function, slow cognitive decline, and facilitate adaptive compensation in deficient brain networks. This chapter provides an overview and critique of the evidence supporting the enhancement of cognitive function at the early symptomatic stage of AD, so-called mild cognitive impairment due to AD (MCI-AD). It reviews the clinical diagnosis of MCI-AD, underscoring the differences between this condition and healthy brain aging and highlighting the importance of fluid and imaging biomarkers in ensuring reliable diagnosis and providing targets for therapeutic modification. Next, it discusses techniques to enhance cognition in MCI, with an emphasis on nonpharmacological interventional approaches. It concludes with a discussion of future challenges and opportunities in the treatment of MCI-AD.

  • [P4–329]: ASSESSING THE IMPACT OF DISCLOSING AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULTS: THE REVEAL‐SCAN STUDY

    by J. Scott Roberts, Robert C. Green, Jason Karlawish, Kathleen A. Welsh‐Bohmer, The Risk Evaluation & Education for Alzheimer's Disease (REVEAL) Study